Expression properties, structural features and functional analysis of CALR E381A in MPN patients.

Kaihong Xu, Qunfang Ge, Yanli Zhang, Guifang Ouyang, Xiao Yan

Abstract read

In one paragraph

Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kaihong XuDepartment of Hematology, Ningbo First Hospital Ningbo, Zhejiang, China.

Qunfang GeDepartment of Hematology, Ningbo First Hospital Ningbo, Zhejiang, China.

Yanli ZhangDepartment of Hematology, Ningbo First Hospital Ningbo, Zhejiang, China.

Guifang OuyangDepartment of Hematology, Ningbo First Hospital Ningbo, Zhejiang, China.

Xiao YanDepartment of Hematology, Ningbo First Hospital Ningbo, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the expression properties, structural features and function of CALR E381A in myeloproliferative neoplasms (MPN) patients.

methodsIn this retrospective study, 435 MPN patients admitted to the Department of Hematology, Ningbo First Hospital from July 2015 to July 2021 were selected as the study subjects. Mutations in

resultsThe predominant types of

conclusionCALR E381A is not a driver mutation for the development of MPN but may be a risk SNP implying an inherited predisposition for MPN disease in East Asian populations.

Indexed as

CALR E381AChinese patientsJAK2 V617FMyeloproliferative neoplasmsingle nucleotide polymorphism

Identifiers

PMID37560236

PMCPMC10408505

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.